<!--StartFragment-->


### **Immune Checkpoints in Cancer: An avenue for Biomarker Discovery**

**By** 

**Nwachuya, Chukwuemeka Augustine**

**Introduction**

Immune checkpoints are essential regulators of the immune system, ensuring that T-cell activation is balanced to prevent autoimmunity while allowing for effective responses against pathogens \[[1](https://www.zotero.org/google-docs/?uwPvGg)]. However, cancer cells can hijack these checkpoints, particularly PD-1 (Programmed Death-1) and CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4), to evade immune surveillance \[[2](https://www.zotero.org/google-docs/?XkBd8p)]. These checkpoints, when activated by ligands like PD-L1, typically expressed on tumour cells, inhibit T-cell activity, allowing tumours to grow unchecked. The understanding of these mechanisms has led to the development of immune checkpoint inhibitors (ICIs), which have transformed cancer therapy by reactivating the immune system to target and destroy cancer cells \[[3](https://www.zotero.org/google-docs/?e9dJRt)].

**Case Study of Immune Checkpoints in Cancer**

The identification of PD-1 and CTLA-4 as key immune checkpoints was a milestone in cancer research. ICIs, such as pembrolizumab (anti-PD-1) and ipilimumab (anti-CTLA-4), work by blocking these inhibitory signals, effectively "releasing the brakes" on the immune system \[[4](https://www.zotero.org/google-docs/?g6UyPP)]. This approach has shown significant efficacy, particularly in cancers like melanoma, where traditional treatments were often ineffective. Patients treated with these ICIs have experienced durable responses, with some achieving long-term remission.

The success of ICIs highlights the importance of immune checkpoints as biomarkers in cancer therapy. PD-L1 expression on tumour cells, for instance, has been used to predict the likelihood of response to anti-PD-1/PD-L1 therapies \[[5](https://www.zotero.org/google-docs/?1CBwO2)]. Patients with higher levels of PD-L1 are generally more responsive to these treatments, making PD-L1 expression a valuable biomarker for guiding treatment decisions. However, not all patients with high PD-L1 expression respond to ICIs, and some with low expression levels do benefit, indicating that PD-L1 alone is not a perfect predictor of treatment success \[[6](https://www.zotero.org/google-docs/?T4PPuP)]. To address these challenges, researchers are investigating additional biomarkers, such as tumour mutational burden and microsatellite instability, which may offer a more comprehensive understanding of a patient's likely response to ICIs. These additional biomarkers, along with PD-L1, can help refine patient selection for immunotherapy, increasing the likelihood of treatment success. The discovery of immune checkpoints has also led to the exploration of combination therapies, where ICIs are used alongside other treatments like chemotherapy or targeted therapies. These combinations aim to overcome resistance and enhance the efficacy of ICIs, offering new hope for patients with difficult-to-treat cancers.

**Conclusion**

Thus, immune checkpoints have revolutionised cancer therapy, providing powerful new tools in the fight against cancer. Their role as biomarkers continues to evolve, and ongoing research promises to further refine and personalise cancer treatment strategies, leading to an improved patient outcomes.

**References**

[1. Sperk M, Domselaar RV, Neogi U. Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection. Int J Mol Sci. 2018 Jul 9;19(7):2000.](https://www.zotero.org/google-docs/?KvMpcs)

[2. Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O’Byrne K, Rezaei N, et al. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 2021 May;41(3):1474–98.](https://www.zotero.org/google-docs/?KvMpcs)

[3. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022 Apr 24;29(5):3044–60.](https://www.zotero.org/google-docs/?KvMpcs)

[4. Basudan AM. The Role of Immune Checkpoint Inhibitors in Cancer Therapy. Clin Pract. 2022 Dec 27;13(1):22–40.](https://www.zotero.org/google-docs/?KvMpcs)

[5. Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018 Dec;17(1):129.](https://www.zotero.org/google-docs/?KvMpcs)

[6. Zhao X, Bao Y, Meng B, Xu Z, Li S, Wang X, et al. From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. Front Immunol. 2022 Aug 3;13:920021.](https://www.zotero.org/google-docs/?KvMpcs)

\


<!--EndFragment-->
